EXPGY vs WAY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
EXPGY is the larger of the two ($32.24B market cap): the incumbent the market prices for continued execution (16.30x forward earnings, beta 0.89). WAY is the smaller challenger ($5.13B), cheaper on forward earnings (14.13x): more room to run, but more to prove. If you believe EXPGY earns its premium (16.3x forward earnings, so the market expects more from it), EXPGY fits. If you believe in paying less for profit, WAY fits at 14.13x.
EXPGY vs WAY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | EXPGY | WAY | What it tells you |
|---|---|---|---|
| Market cap | $32.24B | $5.13B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 16.30 | 14.13 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 21.37 | 38.66 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.89 | 0.11 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 31% of range | 46% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 6.12 | 1.27 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: WAY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how EXPGY and WAY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EXPGY and WAY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EXPGY and WAY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Experian plc (EXPGY) do?
Experian plc runs credit bureaus and the data, analytics and software built on top of them. Lenders pay it for credit reports, scores, identity checks, fraud tools and decisioning software, which make up the B2B side (about 73% of revenue as of the June 2026 quarter). The rest is Consumer Services: free and paid memberships that let people check their credit score and file, plus marketplace referral fees when a member takes out a card or loan through the app. Experian had more than 215 million free consumer members at the end of fiscal 2026. Inside B2B, Financial Services (banks, card issuers, mortgage and auto lenders) is about 53% of group revenue, and Verticals (health, automotive, marketing data, insurance and others) about 20%.
What does Waystar Holding (WAY) do?
Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. Its platform sits between roughly a million providers and the payers that reimburse them, processing billions of transactions a year, and the company leans heavily on automation and AI to reduce the manual work in medical billing. Provider-side solutions make up the large majority of revenue and carry high margins, with patient-payment tools rounding out the mix.
EXPGY vs WAY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- EXPGY drivers: US B2B data and decisioning; Latin America and Serasa.
- WAY drivers: AI-driven revenue cycle automation; Land-and-expand with high retention.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The most immediate risk is FICO. For WAY, concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share.
EXPGY or WAY: which should you pick?
If the story you believe is EXPGY's (US B2B data and decisioning), EXPGY is the more direct way to own it; if it is WAY's (AI-driven revenue cycle automation), WAY is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EXPGY and WAY guides.
EXPGY vs WAY: the full fundamentals
EXPGY. At ~$36.75 per ADR (20 November 2026), Experian trades at roughly 20 times its fiscal 2026 Benchmark EPS of 179.8 cents, about 21 times trailing statutory EPS, and around 16 times forward estimates. That is a lower multiple than the stock has commanded through most of the last decade, and it reflects the FICO licensing change, slower organic growth and the trimmed guidance more than any fall in reported profit: first-half Benchmark EPS grew 15%. Guidance for fiscal 2027 still calls for about 12% Benchmark EPS growth and at least 50 basis points of margin expansion, and the yield is modest because Experian returns more cash through buybacks ($2.5 billion announced in calendar 2026) than through dividends.
WAY. Waystar closed at about $26.72 on November 20, 2026, up about 10% over three months and well above its 52-week low near $17.26, but down roughly 23% from a year earlier. Q3 2026 revenue rose ~21% to ~$326 million and adjusted EPS of $0.44 beat the $0.41 estimate, but the trimmed full-year revenue range sent the stock lower. The trailing GAAP P/E near 39 and a market cap of about 4.1 times trailing revenue reflect expectations for continued double-digit growth, while the forward multiple of about 14 times 2027 adjusted EPS looks lower because adjusted figures exclude amortization and stock compensation; the 22 analysts covering the stock carry a mean target near $34.82, and the price also includes some takeover speculation.
Headline figures (approximate, November 2026): EXPGY shows revenue (fy26, to march 2026) ~$8.45B (+12%; 8% organic), revenue (h1 fy27, to sept 2026) ~$4.45B (+10%; 7% organic), benchmark ebit (h1 fy27) ~$1.28B (+11%; 28.8% margin), benchmark eps (fy26 / h1 fy27) 179.8 US cents (+15%) / 97.5 US cents (+15%); WAY shows revenue (ttm) ~$1.26B (+21% YoY in Q3 2026), q3 2026 adj. eps $0.44 vs $0.41 est., net income (ttm) ~$135M (~11% net margin), q3 2026 adj. ebitda ~$139M (~43% margin).
The bottom line: EXPGY vs WAY
EXPGY and WAY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined EXPGY and WAY exposure against your real portfolio. It is not an investment adviser.
Wondering how EXPGY or WAY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Experian plc
Ask Walnut's AI anything about EXPGY and see how it fits what you own.
FAQ
What is the difference between EXPGY and WAY?
+
Experian plc runs credit bureaus and the data, analytics and software built on top of them. Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is EXPGY or WAY the better stock?
+
Neither is universally better. EXPGY is the larger incumbent; WAY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, EXPGY or WAY?
+
On forward P/E (as of November 2026), EXPGY trades at 16.30x and WAY at 14.13x, so WAY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both EXPGY and WAY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of EXPGY vs WAY?
+
EXPGY: The most immediate risk is FICO. In late 2025 Fair Isaac launched a programme letting mortgage tri-merge resellers calculate and distribute FICO scores directly, bypassing the three bureaus, and Experian's FY26 results cite FICO mortgage royalties as a headwind to margins; Experian shares fell ~4% in London on the day of the announcement, and Jefferies estimated FICO's new models could hit bureau earnings by 10% to 15% on average. The second is slowing growth: organic growth fell from 9% in the last quarter of fiscal 2026 to 7% in both quarters of the first half of fiscal 2027, EMEA and Asia Pacific grew just 3% in the half, and in November Experian narrowed FY27 organic guidance from 6% to 8% down to 6% to 7%, citing higher interest rates and weaker US mortgage volumes. Consumer Services is shrinking in North America while the breach contracts run off. Credit bureaus are regulated businesses, and the US Consumer Financial Protection Bureau, the UK Financial Conduct Authority and Brazilian regulators can change what data may be held and how consumer products are sold; data security is a standing exposure for a company holding files on hundreds of millions of people. Currency matters too, because Experian reports in dollars but earns a meaningful share in reais, sterling and euros. For ADR holders specifically, EXPGY trades OTC (on the OTCQX tier) with thinner volume than the London line, so spreads can be wider; dividends paid directly by the company are subject to 25% Irish dividend withholding tax unless an exemption applies, so the amount received can be lower than the declared rate depending on how the depositary and the holder's paperwork handle it. WAY: Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a trailing P/E near 39 leaves little room for a growth or margin stumble, and the November 2026 reaction to a full-year revenue range about 1% below consensus showed how little slack the market gives. The stock remains well below its 52-week high of about $37.51. Part of its rebound from the spring low followed reports of a possible sale, so a process that ends without a deal could take some of it back. Growth is partly acquisition-fueled and net revenue retention eased to about 108%, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history (about $1.48 billion against roughly $279 million of cash as of September 2026). Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell EXPGY or WAY; figures are approximate and dated (as of November 2026). Verify current data before investing.